Leveraging Degrader Antibody Conjugates for Treating Autoimmune Disease & Addressing Resistance to Conventional ADC Payloads in Oncology
- Harnessing the power of targeted protein degradation to develop novel ADC payloads
- Optimizing degrader payloads to achieve high potency and a favorable safety profile
- Exploring Anti-CD19 DAC demonstrating deep B-cell depletion in animal models
- Evaluating how degrader payloads novel mechanisms can potentially overcome resistance to current TOP1i based ADCs in oncology